Phenylglycine and sulfonamide correctors of defective ΔF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating

Nicoletta Pedemonte, N. D. Sonawane, Alessandro Taddei, Jie Hu, Olga Zegarra-Moran, Yat Fan Suen, Lori I. Robins, Christopher W. Dicus, Dan Willenbring, Michael H. Nantz, Mark J. Kurth, Luis J V Galietta, Alan S. Verkman

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel cause cystic fibrosis. The ΔF508 mutation produces defects in channel gating and cellular processing, whereas the G551D mutation produces primarily a gating defect. To identify correctors of gating, 50,000 diverse small molecules were screened at 2.5 μM (with forskolin, 20 μM) by an iodide uptake assay in epithelial cells coexpressing ΔF508-CFTR and a fluorescent halide indicator (yellow fluorescent protein-H148Q/I152L) after ΔF508-CFTR rescue by 24-h culture at 27°C. Secondary analysis and testing of > 1000 structural analogs yielded two novel classes of correctors of defective ΔF508-CFTR gating ("potentiators") with nanomolar potency that were active in human ΔF508 and G551D cells. The most potent compound of the phenylglycine class, 2-[(2-1H-indol-3-yl-acetyl)-methylamino]-N- (4-isopropylphenyl)-2-phenylacetamide, reversibly activated ΔF508-CFTR in the presence of forskolin with Ka ∼ 70 nM and also activated the CFTR gating mutants G551D and G1349D with Ka values of ∼1100 and 40 nM, respectively. The most potent sulfonamide, 6-(ethylphenylsulfamoyl)-4- oxo-1,4-dihydroquinoline-3-carboxylic acid cycloheptylamide, had Ka ∼ 20 nM for activation of ΔF508-CFTR. In cell-attached patch-clamp experiments, phenylglycine-01 (PG-01) and sulfonamide-01 (SF-01) increased channel open probability >5-fold by the reduction of interburst closed time. An interesting property of these compounds was their ability to act in synergy with cAMP agonists. Microsome metabolism studies and rat pharmacokinetic analysis suggested significantly more rapid metabolism of PG-01 than SF-03. Phenylglycine and sulfonamide compounds may be useful for monotherapy of cystic fibrosis caused by gating mutants and possibly for a subset of ΔF508 subjects with significant ΔF508-CFTR plasma-membrane expression.

Original languageEnglish (US)
Pages (from-to)1797-1807
Number of pages11
JournalMolecular Pharmacology
Volume67
Issue number5
DOIs
StatePublished - May 2005

Fingerprint

Cystic Fibrosis Transmembrane Conductance Regulator
Chloride Channels
Sulfonamides
Colforsin
Cystic Fibrosis
Mutation
Iodides
Carboxylic Acids
Microsomes
Pharmacokinetics
Epithelial Cells
Cell Membrane

ASJC Scopus subject areas

  • Pharmacology

Cite this

Phenylglycine and sulfonamide correctors of defective ΔF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. / Pedemonte, Nicoletta; Sonawane, N. D.; Taddei, Alessandro; Hu, Jie; Zegarra-Moran, Olga; Suen, Yat Fan; Robins, Lori I.; Dicus, Christopher W.; Willenbring, Dan; Nantz, Michael H.; Kurth, Mark J.; Galietta, Luis J V; Verkman, Alan S.

In: Molecular Pharmacology, Vol. 67, No. 5, 05.2005, p. 1797-1807.

Research output: Contribution to journalArticle

Pedemonte, N, Sonawane, ND, Taddei, A, Hu, J, Zegarra-Moran, O, Suen, YF, Robins, LI, Dicus, CW, Willenbring, D, Nantz, MH, Kurth, MJ, Galietta, LJV & Verkman, AS 2005, 'Phenylglycine and sulfonamide correctors of defective ΔF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating', Molecular Pharmacology, vol. 67, no. 5, pp. 1797-1807. https://doi.org/10.1124/mol.105.010959
Pedemonte, Nicoletta ; Sonawane, N. D. ; Taddei, Alessandro ; Hu, Jie ; Zegarra-Moran, Olga ; Suen, Yat Fan ; Robins, Lori I. ; Dicus, Christopher W. ; Willenbring, Dan ; Nantz, Michael H. ; Kurth, Mark J. ; Galietta, Luis J V ; Verkman, Alan S. / Phenylglycine and sulfonamide correctors of defective ΔF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. In: Molecular Pharmacology. 2005 ; Vol. 67, No. 5. pp. 1797-1807.
@article{b6db2c108a234ab183b4416f406dedee,
title = "Phenylglycine and sulfonamide correctors of defective ΔF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating",
abstract = "Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel cause cystic fibrosis. The ΔF508 mutation produces defects in channel gating and cellular processing, whereas the G551D mutation produces primarily a gating defect. To identify correctors of gating, 50,000 diverse small molecules were screened at 2.5 μM (with forskolin, 20 μM) by an iodide uptake assay in epithelial cells coexpressing ΔF508-CFTR and a fluorescent halide indicator (yellow fluorescent protein-H148Q/I152L) after ΔF508-CFTR rescue by 24-h culture at 27°C. Secondary analysis and testing of > 1000 structural analogs yielded two novel classes of correctors of defective ΔF508-CFTR gating ({"}potentiators{"}) with nanomolar potency that were active in human ΔF508 and G551D cells. The most potent compound of the phenylglycine class, 2-[(2-1H-indol-3-yl-acetyl)-methylamino]-N- (4-isopropylphenyl)-2-phenylacetamide, reversibly activated ΔF508-CFTR in the presence of forskolin with Ka ∼ 70 nM and also activated the CFTR gating mutants G551D and G1349D with Ka values of ∼1100 and 40 nM, respectively. The most potent sulfonamide, 6-(ethylphenylsulfamoyl)-4- oxo-1,4-dihydroquinoline-3-carboxylic acid cycloheptylamide, had Ka ∼ 20 nM for activation of ΔF508-CFTR. In cell-attached patch-clamp experiments, phenylglycine-01 (PG-01) and sulfonamide-01 (SF-01) increased channel open probability >5-fold by the reduction of interburst closed time. An interesting property of these compounds was their ability to act in synergy with cAMP agonists. Microsome metabolism studies and rat pharmacokinetic analysis suggested significantly more rapid metabolism of PG-01 than SF-03. Phenylglycine and sulfonamide compounds may be useful for monotherapy of cystic fibrosis caused by gating mutants and possibly for a subset of ΔF508 subjects with significant ΔF508-CFTR plasma-membrane expression.",
author = "Nicoletta Pedemonte and Sonawane, {N. D.} and Alessandro Taddei and Jie Hu and Olga Zegarra-Moran and Suen, {Yat Fan} and Robins, {Lori I.} and Dicus, {Christopher W.} and Dan Willenbring and Nantz, {Michael H.} and Kurth, {Mark J.} and Galietta, {Luis J V} and Verkman, {Alan S.}",
year = "2005",
month = "5",
doi = "10.1124/mol.105.010959",
language = "English (US)",
volume = "67",
pages = "1797--1807",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "5",

}

TY - JOUR

T1 - Phenylglycine and sulfonamide correctors of defective ΔF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating

AU - Pedemonte, Nicoletta

AU - Sonawane, N. D.

AU - Taddei, Alessandro

AU - Hu, Jie

AU - Zegarra-Moran, Olga

AU - Suen, Yat Fan

AU - Robins, Lori I.

AU - Dicus, Christopher W.

AU - Willenbring, Dan

AU - Nantz, Michael H.

AU - Kurth, Mark J.

AU - Galietta, Luis J V

AU - Verkman, Alan S.

PY - 2005/5

Y1 - 2005/5

N2 - Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel cause cystic fibrosis. The ΔF508 mutation produces defects in channel gating and cellular processing, whereas the G551D mutation produces primarily a gating defect. To identify correctors of gating, 50,000 diverse small molecules were screened at 2.5 μM (with forskolin, 20 μM) by an iodide uptake assay in epithelial cells coexpressing ΔF508-CFTR and a fluorescent halide indicator (yellow fluorescent protein-H148Q/I152L) after ΔF508-CFTR rescue by 24-h culture at 27°C. Secondary analysis and testing of > 1000 structural analogs yielded two novel classes of correctors of defective ΔF508-CFTR gating ("potentiators") with nanomolar potency that were active in human ΔF508 and G551D cells. The most potent compound of the phenylglycine class, 2-[(2-1H-indol-3-yl-acetyl)-methylamino]-N- (4-isopropylphenyl)-2-phenylacetamide, reversibly activated ΔF508-CFTR in the presence of forskolin with Ka ∼ 70 nM and also activated the CFTR gating mutants G551D and G1349D with Ka values of ∼1100 and 40 nM, respectively. The most potent sulfonamide, 6-(ethylphenylsulfamoyl)-4- oxo-1,4-dihydroquinoline-3-carboxylic acid cycloheptylamide, had Ka ∼ 20 nM for activation of ΔF508-CFTR. In cell-attached patch-clamp experiments, phenylglycine-01 (PG-01) and sulfonamide-01 (SF-01) increased channel open probability >5-fold by the reduction of interburst closed time. An interesting property of these compounds was their ability to act in synergy with cAMP agonists. Microsome metabolism studies and rat pharmacokinetic analysis suggested significantly more rapid metabolism of PG-01 than SF-03. Phenylglycine and sulfonamide compounds may be useful for monotherapy of cystic fibrosis caused by gating mutants and possibly for a subset of ΔF508 subjects with significant ΔF508-CFTR plasma-membrane expression.

AB - Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel cause cystic fibrosis. The ΔF508 mutation produces defects in channel gating and cellular processing, whereas the G551D mutation produces primarily a gating defect. To identify correctors of gating, 50,000 diverse small molecules were screened at 2.5 μM (with forskolin, 20 μM) by an iodide uptake assay in epithelial cells coexpressing ΔF508-CFTR and a fluorescent halide indicator (yellow fluorescent protein-H148Q/I152L) after ΔF508-CFTR rescue by 24-h culture at 27°C. Secondary analysis and testing of > 1000 structural analogs yielded two novel classes of correctors of defective ΔF508-CFTR gating ("potentiators") with nanomolar potency that were active in human ΔF508 and G551D cells. The most potent compound of the phenylglycine class, 2-[(2-1H-indol-3-yl-acetyl)-methylamino]-N- (4-isopropylphenyl)-2-phenylacetamide, reversibly activated ΔF508-CFTR in the presence of forskolin with Ka ∼ 70 nM and also activated the CFTR gating mutants G551D and G1349D with Ka values of ∼1100 and 40 nM, respectively. The most potent sulfonamide, 6-(ethylphenylsulfamoyl)-4- oxo-1,4-dihydroquinoline-3-carboxylic acid cycloheptylamide, had Ka ∼ 20 nM for activation of ΔF508-CFTR. In cell-attached patch-clamp experiments, phenylglycine-01 (PG-01) and sulfonamide-01 (SF-01) increased channel open probability >5-fold by the reduction of interburst closed time. An interesting property of these compounds was their ability to act in synergy with cAMP agonists. Microsome metabolism studies and rat pharmacokinetic analysis suggested significantly more rapid metabolism of PG-01 than SF-03. Phenylglycine and sulfonamide compounds may be useful for monotherapy of cystic fibrosis caused by gating mutants and possibly for a subset of ΔF508 subjects with significant ΔF508-CFTR plasma-membrane expression.

UR - http://www.scopus.com/inward/record.url?scp=20944442087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20944442087&partnerID=8YFLogxK

U2 - 10.1124/mol.105.010959

DO - 10.1124/mol.105.010959

M3 - Article

C2 - 15722457

AN - SCOPUS:20944442087

VL - 67

SP - 1797

EP - 1807

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 5

ER -